What is NEO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 2.17B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for NEO?

P/E (TTM) is n/a and 52-week range is $7.07 to $20.15 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s NEO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for NEO?

The company profile lists revenue (TTM) near $753M, net income (TTM) near $-5.09B, EPS (TTM) near $-0.40 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Neogenomics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Fort Myers, Florida, US, 128.5M shares outstanding, ISIN US64049M2098 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Neogenomics Inc

$NEO

Health Care · Health Care Providers & Services

IR Run Scenarios

$16.88

+1.32%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,500 full-time employees. The company went IPO on 2012-12-10. The firm offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. The company operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.

Employees

2,500

Website

neogenomics.com/

IPO

2012-12-10

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)